Report Id: SNS/HC/1289 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
CMO/CDMO Market Size was valued at USD 18.92 Billion in 2022 and is expected to reach USD 41.75 Billion by 2030, and grow at a CAGR of 10.4% over the forecast period 2023-2030.
CMOs and CDMOs are companies that take a pre-formulated drug and produce it, whereas CDMOs are companies that create and manufacture drugs. Throughout the projection period, rising demand for face care creams and sunscreen lotions, as well as the requirement for cutting-edge procedures and production technology, has led to the adoption of CMO/CDMO. For example: When compared to more than 100 various industries, pharmaceutical industries in the United States had the tenth highest average after-tax profit levels in 2021, according to Axios, a significant online news firm in the United States. Drug corporations earn 68 percent of the overall profits in the United States, although accounting for only 29 percent of total sales.
In addition, as the demand for generic medications and biologics grows, the acceptance and demand for CMO/CDMO is expected to rise during the projection period. Government regulations, on the other hand, will stifle market growth between 2022 and 2028.
One of the fastest-growing domains will be skin products.
The market is growing due to increased expenditure in pharmaceutical R&D
Pharmaceutical businesses will use CMO/CDMO services for drug development.
The issue for CMOs and CDMOs is to provide a reliable serialisation procedure.
Manufacturing of novel biologics and biosimilars is experiencing rapid increase.
Beauty care products and individual consideration items are popular.
Rules and regulation of government
IMPACT OF COVID-19
Due to technological improvements and the COVID-19 pandemic, specialized enterprises are emerging at high annual rates. Local governments and businesses are allocating a large amount of money to expand existing facilities and build new ones in order to combat the COVID-19 outbreak. Furthermore, technical improvements have made it a priority to improve CDMO capabilities.
Furthermore, price differences in contract services are due to the nature of biopharmaceuticals, cell-line technology, and CDMO type. As a result of the COVID-19 epidemic, contract service pricing is projected to rise, with longer lead times for slot availability.
As a result, the COVID-19 pandemic has shifted national healthcare objectives and spending, but this is only expected to have a short-term negative impact on market growth because COVID-19 vaccine development was prioritized.
Therefore, in order to meet the growing demand for biologics manufacturing, consolidation activities and the expansion of international manufacturing capacity have increased. As a result of these causes, the CMO/CDMO industry grew during the pandemic crisis.
Over the projected period, monoclonal antibodies are expected to lead the market with a 49 percent market share. This is due to a high rate of success in the development and approval of monoclonal antibody therapies, as well as the introduction of biosimilars in the United States and Europe.
Over the forecast period, standalone services would command a market share of 65 percent. The growth of cell-line development services by biopharmaceutical and biotechnology businesses is mostly responsible for this segment's size.
Some of the major key players are as follows: Piramal Pharma Solutions, Samsung Biologics, Eurofins Scientific, mAbxience, Lonza, CoreRx, AXXELENT, Laurus Synthesis, KBI Biopharma., Sai Life Sciences, Idifarma, QuayPharma, BDR Pharmaceuticals Internationals Pvt. Ltd., HIKAL Ltd.
KEY MARKET SEGMENTATION:
On the Basis of Service:
Clinical Trail Services
Finished Dosage Manufacturing
Injectable Drug Manufacturing
Tablet & Capsule Manufacturing
Topical Drug Manufacturing
On the Basis of End User:
Large Pharma Companies
Mid-Sized Pharma Companies
The greatest market for CMO/CDMO services is in North America. The growing demand from the pharmaceutical and biotechnology sectors is propelling this market forward. Furthermore, the increasing number of generic medicine approvals is driving up demand for contract development and manufacturing services in this region.
During the projection period, the Latin American market for CMO/CDMO services is expected to grow at a rapid rate. This is due to rising healthcare spending and increased investments in drug research projects in countries such as Brazil and Mexico.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 18.92 Billion|
|Market Size by 2030||US$ 41.75 Billion|
|CAGR||CAGR of 10.4% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Service (Contract Development (R&D Services, Clinical Trail Services, Pre-Formulation Studies, others), Contract Manufacturing (API Manufacturing, Finished Dosage Manufacturing, Injectable Drug Manufacturing, Tablet & Capsule Manufacturing, Liquid Manufacturing, Topical Drug Manufacturing)
• By End User (Large Pharma Companies, Mid-Sized Pharma Companies, Biotechnology Companies, others)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Piramal Pharma Solutions, Samsung Biologics, Eurofins Scientific, mAbxience, Lonza, CoreRx, AXXELENT, Laurus Synthesis, KBI Biopharma., Sai Life Sciences, Idifarma, QuayPharma, BDR Pharmaceuticals Internationals Pvt. Ltd., HIKAL Ltd.|
|DRIVERS||• One of the fastest-growing domains will be skin products.
• The market is growing due to increased expenditure in pharmaceutical R&D
• Pharmaceutical businesses will use CMO/CDMO services for drug development.
|RESTRAINTS||• The issue for CMOs and CDMOs is to provide a reliable serialisation procedure.|
Frequently Asked Questions (FAQ) :
The issue for CMOs and CDMOs is to provide a reliable serialisation procedure are the main restraints of the CMO/CDMO market.
One of the fastest growing domains will be skin products, The market is growing due to increased expenditure in pharmaceutical R&D all propelling CMO/CDMO market forward.
The greatest market for CMO/CDMO services is in North America. The growing demand from the pharmaceutical and biotechnology sectors is propelling this market forward.
Boehringer Ingelheim, Catalent, Lonza., KBI Biopharma (JSR Corporation), Samsung Biologics Co., Ltd, Cytovance Biologics, Xpress Biologic are the key players of the CMO/CDMO Market.
CMO/CDMO Market Size was valued at USD 17.14 billion in 2021.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
184.108.40.206 United Kingdom
220.127.116.11 South Korea
18.104.22.168 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global CMO/CDMO Market Segmentation, By Service
8.1 Contract Development
8.1.1 R&D Services
8.1.2 Clinical Trail Services
8.1.3 Pre-Formulation Studies
8.2 Contract Manufacturing
8.2.1 API Manufacturing
8.2.2 Finished Dosage Manufacturing
8.2.3 Injectable Drug Manufacturing
8.2.4 Tablet & Capsule Manufacturing
8.2.5 Liquid Manufacturing
8.2.6 Topical Drug Manufacturing
9. Global CMO/CDMO Market Segmentation, By End User
9.1 Large Pharma Companies
9.2 Mid-Sized Pharma Companies
9.3 Biotechnology Companies
10. Regional Analysis
10.2 North America
10.3.6 The Netherlands
10.3.7 Rest of Europe
10.4.2 South Korea
10.4.6 Rest of Asia-Pacific
10.5 The Middle East & Africa
10.5.3 South Africa
10.6 Latin America
10.6.3 Rest of Latin America
11. Company Profiles
11.1 Piramal Pharma Solutions
11.2 Samsung Biologics
11.3 Eurofins Scientific
11.8 Laurus Synthesis
11.9 KBI Biopharma.
11.10 Sai Life Sciences
11.13 BDR Pharmaceuticals Internationals Pvt. Ltd.
11.14 HIKAL Ltd.
12. Competitive Landscape
12.1 Competitive Benchmark
12.2 Market Share Analysis
12.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.